Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Tiziana takes a deep breath and targets Covid-19
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Abbvie manoeuvres to defend Humira to the last
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Forecasts tell a tale of two continents for biosimilars
Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.
